網膜芽細胞腫治療の世界市場レポート 2025年

網膜芽細胞腫治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.8％で27億米ドルに成長します。予測期間の成長は、眼科治療や手術の需要増加、網膜芽細胞腫の発生率増加、研究開発活動の活発化、網膜芽細胞腫治療に関する意識の高まり、ヘルスケア支出の増加に起因しています。予測期間における主な動向としては、医療技術の進歩、診断能力の向上、小児腫瘍学への投資の増加、新製品の承認、医療インフラの改善などが挙げられます。

眼科治療や手術に対するニーズの高まりが、当面の網膜芽細胞腫治療市場の拡大を牽引すると予測されます。眼科治療・手術には、目や視覚系に影響を及ぼす疾患の診断、管理、矯正を目的としたさまざまな医療介入や処置が含まれます。このような需要の急増は、人口の高齢化、白内障や加齢黄斑変性などの疾患の有病率の増加、より効率的で利用しやすい治療を可能にする技術の進歩、早期発見と早期介入につながる意識の高まりなどの要因によるものです。網膜芽細胞腫治療は、眼球内のがん増殖に対処し、転移や再発を防ぐと同時に、視力や眼球機能を維持することを目的とした眼科手術に不可欠です。例えば、2023年9月、英国の健康改善・格差対策室からの報告書によると、イングランドにおける白内障手術の入院患者数は409万人を超え、2022年までの会計年度における人口10万人当たりの入院患者数は3,803人（3,789人～3,816人）でした。さらに、同期間中に実施された網膜剥離手術の入院件数は1万900件超、硝子体内注射療法の実施件数は67万7,000件超で、それぞれ人口10万人当たりの割合は23.4（22.9～24.0）、4,796（4,769～4,823）でした。その結果、眼科治療や手術に対する需要の高まりが網膜芽細胞腫治療市場の成長を後押ししています。

網膜芽細胞腫治療市場の主なプレーヤーは、強化された機能性で顧客の進化するニーズに応えるために、腫瘍溶解性アデノウイルスのような革新的なソリューションの開発に専念しています。腫瘍溶解性アデノウイルスは、正常細胞を温存しながらがん細胞に感染し、選択的に破壊するように設計された遺伝子組み換えウイルスです。例えば、2022年2月、スペインに本社を置くバイオテクノロジー企業であるVCNバイオサイエンシズは、網膜芽細胞腫治療用に意図された遺伝子組み換えのオンコリティック・アデノウイルスであるVCN-01について、米国食品医薬品局から希少疾病用医薬品の指定を受けた。VCN-01の特徴は、そのオンコリティック・アデノウイルスという性質にあり、現在、膵臓がんや網膜芽細胞腫（RB）など、決定的な治療法のないがんを対象に臨床試験が行われています。VCN-01は4つの第1相臨床試験で精査を受けており、化学療法が奏功しなかったRB患者に対する単独治療オプションとして検討されています。VCN-01の硝子体内投与により、複数の患者で完全寛解と腫瘍縮小が確認され、希少疾病用医薬品の承認への道が開かれました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界網膜芽細胞腫治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の網膜芽細胞腫治療市場：成長率分析
• 世界の網膜芽細胞腫治療市場の実績：規模と成長, 2019-2024
• 世界の網膜芽細胞腫治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界網膜芽細胞腫治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の網膜芽細胞腫治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非遺伝性網膜芽細胞腫
• 遺伝性網膜芽細胞腫
• 世界の網膜芽細胞腫治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 放射線治療
• レーザー治療（光凝固術）
• 凍結療法
• 温熱療法
• 化学療法
• 眼動脈注入化学療法
• 高用量化学療法と幹細胞移植
• 世界の網膜芽細胞腫治療市場病気のステージ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 眼内網膜芽細胞腫
• 眼球外網膜芽細胞腫
• 世界の網膜芽細胞腫治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がん研究所
• その他の用途
• 世界の網膜芽細胞腫治療市場非遺伝性網膜芽細胞腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 片側性非遺伝性網膜芽細胞腫
• 両側性非遺伝性網膜芽細胞腫
• 世界の網膜芽細胞腫治療市場遺伝性網膜芽細胞腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 両側性遺伝性網膜芽細胞腫
• 片側性遺伝性網膜芽細胞腫

第7章 地域別・国別分析

• 世界の網膜芽細胞腫治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の網膜芽細胞腫治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 網膜芽細胞腫治療市場：競合情勢
• 網膜芽細胞腫治療市場：企業プロファイル
  • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline Plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Baxter International Inc.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Otsuka Pharmaceutical
• Daiichi Sankyo Company
• Taiho Pharmaceutical Co. Ltd.
• Icon Bioscience Inc.
• Ono Pharmaceutical Co. Ltd.
• Nippon Shinyaku Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 網膜芽細胞腫治療市場2029：新たな機会を提供する国
• 網膜芽細胞腫治療市場2029：新たな機会を提供するセグメント
• 網膜芽細胞腫治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Retinoblastoma treatment encompasses medical interventions and therapies directed at diagnosing, managing, and potentially curing retinoblastoma, a rare type of eye cancer predominantly found in young children, typically before the age of five. The primary objective of retinoblastoma treatment is to eliminate or control the cancerous growths within the eye(s) while preserving vision and minimizing the risk of metastasis or recurrence.

The main types of retinoblastoma treatment include non-hereditary retinoblastoma and hereditary retinoblastoma. Non-hereditary retinoblastoma, a rare cancer affecting children under six years old, encompasses various treatment modalities such as surgery, radiation therapy, laser therapy (photocoagulation), cryotherapy, thermotherapy, chemotherapy, ophthalmic artery infusion chemotherapy, and high-dose chemotherapy with stem cell transplant. These treatments are applicable to both intraocular and extraocular retinoblastoma stages and are commonly administered in hospitals, cancer institutes, and other medical facilities.

The retinoblastoma treatment market research report is one of a series of new reports from The Business Research Company that provides retinoblastoma treatment market statistics, including retinoblastoma treatment industry global market size, regional shares, competitors with a retinoblastoma treatment market share, detailed retinoblastoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the retinoblastoma treatment industry. This retinoblastoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The retinoblastoma treatment market size has grown strongly in recent years. It will grow from $2.03 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to increasing number of funding, chance of recurrence of retinoblastoma, early diagnosis and treatment of retinoblastoma, growing awareness regarding different type of cancers, considerable growth in cancer research.

The retinoblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.7 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to increasing demand for ophthalmic treatment and surgeries, increasing incidence of retinoblastoma, increasing research and development activities, growing awareness pertaining to retinoblastoma treatment, increasing healthcare expenditure. Major trends in the forecast period include advancements in medical technology, improved diagnostic capabilities, augmented investments in pediatric oncology, new product approval, improvements in medical infrastructure.

The rising need for ophthalmic treatment and surgeries is anticipated to drive the expansion of the retinoblastoma treatment market in the foreseeable future. Ophthalmic treatment and surgeries encompass a range of medical interventions and procedures aimed at diagnosing, managing, and correcting disorders affecting the eyes and visual system. This demand surge is attributed to factors such as an aging population, increased prevalence of conditions such as cataracts and age-related macular degeneration, technological advancements enabling more efficient and accessible treatments, and heightened awareness leading to earlier detection and intervention. Retinoblastoma treatment is essential for ophthalmic surgeries aimed at addressing cancerous growths within the eye(s), preventing metastasis or recurrence, while also preserving vision and eye function. For example, in September 2023, a report from the UK's Office for Health Improvement and Disparities revealed over 4.09 million admissions for cataract surgery in England, with a rate of 3,803 (3,789 to 3,816) per 100,000 population in the financial year ending 2022. Additionally, there were over 10,900 admissions for rhegmatogenous retinal detachment surgeries and over 677,000 intravitreal injection therapy procedures performed during the same period, with rates of 23.4 (22.9 to 24.0) and 4,796 (4,769 to 4,823) per 100,000 population, respectively. Consequently, the rising demand for ophthalmic treatment and surgeries is propelling the growth of the retinoblastoma treatment market.

Key players in the retinoblastoma treatment market are dedicated to developing innovative solutions, such as oncolytic adenovirus, to cater to the evolving needs of customers with enhanced functionalities. An oncolytic adenovirus is a genetically modified virus designed to infect and selectively destroy cancer cells while sparing normal cells. For instance, in February 2022, VCN Biosciences, a biotechnology company based in Spain, received orphan drug designation from the U.S. Food and Drug Administration for VCN-01, a genetically engineered oncolytic adenovirus intended for retinoblastoma treatment. VCN-01's distinctive feature lies in its oncolytic adenovirus nature, which is currently undergoing clinical trials targeting cancers with no definitive cure, including pancreatic carcinoma and retinoblastoma (RB). VCN-01 has undergone scrutiny in four phase 1 clinical trials and is being investigated as a standalone treatment option for RB patients who have previously undergone unsuccessful chemotherapy. Intravitreal administration of VCN-01 has demonstrated complete remission and tumor reduction in several patients, paving the way for its orphan drug status approval.

In March 2022, Synthetic Biologics Inc., a biotechnology company based in the United States, acquired VCN Biosciences S.L. for an undisclosed sum. This acquisition represents a significant advancement in Synthetic Biologics' pipeline, integrating VCN's primary clinical-stage drug candidate, VCN-01. VCN Biosciences S.L. is a biotechnology company based in Spain specializing in retinoblastoma treatment.

Major companies operating in the retinoblastoma treatment market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Baxter International Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Otsuka Pharmaceutical, Daiichi Sankyo Company, Taiho Pharmaceutical Co. Ltd., Icon Bioscience Inc., Ono Pharmaceutical Co. Ltd., Nippon Shinyaku Co. Ltd., Cadila Pharmaceuticals, Arcus Biosciences Inc., Sheba Medical Center, Cellceutix Corporation, Phio Pharmaceuticals Inc.

North America was the largest region in the retinoblastoma treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the retinoblastoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the retinoblastoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The retinoblastoma treatment market consists of revenues earned by entities by providing services such as multidisciplinary care, genetic testing and counseling, remote patient monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The retinoblastoma treatment market also includes sales of targeted therapy medications, genetic testing kits and intravitreal chemotherapy injections. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Retinoblastoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on retinoblastoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for retinoblastoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The retinoblastoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Non-Hereditary Retinoblastoma; Hereditary Retinoblastoma
• 2) By Treatment Type: Surgery; Radiation Therapy; Laser Therapy (Photocoagulation); Cryotherapy; Thermotherapy; Chemotherapy; Ophthalmic Artery Infusion Chemotherapy; High-Dose Chemotherapy And Stem Cell Transplant
• 3) By Disease Stage: Intraocular Retinoblastoma; Extraocular Retinoblastoma
• 4) By Application: Hospitals; Cancer Institutes; Other Applications
• Subsegments:
• 1) By Non-Hereditary Retinoblastoma: Unilateral Non-Hereditary Retinoblastoma; Bilateral Non-Hereditary Retinoblastoma
• 2) By Hereditary Retinoblastoma: Bilateral Hereditary Retinoblastoma; Unilateral Hereditary Retinoblastoma
• Companies Mentioned: Johnson & Johnson Services Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Retinoblastoma Treatment Market Characteristics

3. Retinoblastoma Treatment Market Trends And Strategies

4. Retinoblastoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Retinoblastoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Retinoblastoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Retinoblastoma Treatment Market Growth Rate Analysis
• 5.4. Global Retinoblastoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Retinoblastoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Retinoblastoma Treatment Total Addressable Market (TAM)

6. Retinoblastoma Treatment Market Segmentation

• 6.1. Global Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Hereditary Retinoblastoma
• Hereditary Retinoblastoma
• 6.2. Global Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Laser Therapy (Photocoagulation)
• Cryotherapy
• Thermotherapy
• Chemotherapy
• Ophthalmic Artery Infusion Chemotherapy
• High-Dose Chemotherapy And Stem Cell Transplant
• 6.3. Global Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intraocular Retinoblastoma
• Extraocular Retinoblastoma
• 6.4. Global Retinoblastoma Treatment Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Institutes
• Other Applications
• 6.5. Global Retinoblastoma Treatment Market, Sub-Segmentation Of Non-Hereditary Retinoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Unilateral Non-Hereditary Retinoblastoma
• Bilateral Non-Hereditary Retinoblastoma
• 6.6. Global Retinoblastoma Treatment Market, Sub-Segmentation Of Hereditary Retinoblastoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bilateral Hereditary Retinoblastoma
• Unilateral Hereditary Retinoblastoma

7. Retinoblastoma Treatment Market Regional And Country Analysis

• 7.1. Global Retinoblastoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Retinoblastoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Retinoblastoma Treatment Market

• 8.1. Asia-Pacific Retinoblastoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Retinoblastoma Treatment Market

• 9.1. China Retinoblastoma Treatment Market Overview
• 9.2. China Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Retinoblastoma Treatment Market

• 10.1. India Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Retinoblastoma Treatment Market

• 11.1. Japan Retinoblastoma Treatment Market Overview
• 11.2. Japan Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Retinoblastoma Treatment Market

• 12.1. Australia Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Retinoblastoma Treatment Market

• 13.1. Indonesia Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Retinoblastoma Treatment Market

• 14.1. South Korea Retinoblastoma Treatment Market Overview
• 14.2. South Korea Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Retinoblastoma Treatment Market

• 15.1. Western Europe Retinoblastoma Treatment Market Overview
• 15.2. Western Europe Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Retinoblastoma Treatment Market

• 16.1. UK Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Retinoblastoma Treatment Market

• 17.1. Germany Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Retinoblastoma Treatment Market

• 18.1. France Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Retinoblastoma Treatment Market

• 19.1. Italy Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Retinoblastoma Treatment Market

• 20.1. Spain Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Retinoblastoma Treatment Market

• 21.1. Eastern Europe Retinoblastoma Treatment Market Overview
• 21.2. Eastern Europe Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Retinoblastoma Treatment Market

• 22.1. Russia Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Retinoblastoma Treatment Market

• 23.1. North America Retinoblastoma Treatment Market Overview
• 23.2. North America Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Retinoblastoma Treatment Market

• 24.1. USA Retinoblastoma Treatment Market Overview
• 24.2. USA Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Retinoblastoma Treatment Market

• 25.1. Canada Retinoblastoma Treatment Market Overview
• 25.2. Canada Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Retinoblastoma Treatment Market

• 26.1. South America Retinoblastoma Treatment Market Overview
• 26.2. South America Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Retinoblastoma Treatment Market

• 27.1. Brazil Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Retinoblastoma Treatment Market

• 28.1. Middle East Retinoblastoma Treatment Market Overview
• 28.2. Middle East Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Retinoblastoma Treatment Market

• 29.1. Africa Retinoblastoma Treatment Market Overview
• 29.2. Africa Retinoblastoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Retinoblastoma Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Retinoblastoma Treatment Market, Segmentation By Disease Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Retinoblastoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Retinoblastoma Treatment Market Competitive Landscape
• 30.2. Retinoblastoma Treatment Market Company Profiles
  • 30.2.1. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Retinoblastoma Treatment Market Other Major And Innovative Companies

• 31.1. Novartis AG
• 31.2. Pfizer Inc.
• 31.3. GlaxoSmithKline Plc
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Teva Pharmaceutical Industries Ltd.
• 31.7. Baxter International Inc.
• 31.8. Regeneron Pharmaceuticals Inc.
• 31.9. Astellas Pharma Inc.
• 31.10. Otsuka Pharmaceutical
• 31.11. Daiichi Sankyo Company
• 31.12. Taiho Pharmaceutical Co. Ltd.
• 31.13. Icon Bioscience Inc.
• 31.14. Ono Pharmaceutical Co. Ltd.
• 31.15. Nippon Shinyaku Co. Ltd.

32. Global Retinoblastoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Retinoblastoma Treatment Market

34. Recent Developments In The Retinoblastoma Treatment Market

35. Retinoblastoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Retinoblastoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Retinoblastoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Retinoblastoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer